# Maggie C.U. Cheang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maggie-c-u-cheang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,366 |
| Field | Breast Cancer Treatment Studies |
| h-index | 64 |
| i10-index | 115 |
| Last Known Institution | Institute of Cancer Research |
| OpenAlex ID | https://openalex.org/A5019349196 |
| ORCID iD | https://orcid.org/0000-0001-5718-2501 |
| Works | 456 |

## Researcher papers

- [Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study](https://scholariq.org/papers/race-breast-cancer-subtypes-and-survival-in-the-carolina-breast-cancer-study/)
- [Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma](https://scholariq.org/papers/immunohistochemical-and-clinical-characterization-of-the-basal-like-subtype-of/)
- [Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies](https://scholariq.org/papers/subtyping-of-breast-cancer-by-immunohistochemistry-to-investigate-a-relationship/)
- [Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer](https://scholariq.org/papers/mutation-tracking-in-circulating-tumor-dna-predicts-relapse-in-early-breast/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Institute of Cancer Research](https://scholariq.org/institutions/institute-of-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.